<DOC>
	<DOCNO>NCT00847444</DOCNO>
	<brief_summary>This open-label , multicenter , 2x2 factorial design , randomize control , Phase III study compare disease free survival randomisation patient treat 3 cycle Epirubicine-Fluorouracil-Cyclophosphamide ( FEC ) -chemotherapy , follow 3 cycle Docetaxel ( D ) -chemotherapy , versus 6 cycle Docetaxel- Cyclophosphamide ( DC ) -chemotherapy , compare disease free survival patient BMI 24 - 40 kg/m² randomisation versus without lifestyle intervention . Patients required histopathological proof HER2/neu negative tumor : axillary lymph node metastasis ( pN1-3 ) high risk node negative , define : 'pT ≥2 histopathological grade 3 , age ≤35 negative hormone receptor status , allow evidence distant disease . Patients enter study later 6 week complete resection primary tumor . No antineoplastic treatment surgical treatment , define cytotoxic endocrine treatment radiotherapy allow prior study entry course study .</brief_summary>
	<brief_title>Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation , Well Life Style Intervention</brief_title>
	<detailed_description>Rationale : - Taxane base chemotherapy establish treatment standard adjuvant set early breast cancer - 3xFEC100 , follow 3xDoc100 establish standard treatment option node-positive breast cancer - Anthracycline base regimen seem superior Her2/neu-negative patient ( Gennari et al. , Slamon et al . ) - Dietary intervention improve outcome patient early breast cancer ( WINS , Chlebowski et al . ) Primary Endpoints : - The first primary objective study compare disease free survival randomisation patient treated combination 5-FU/Epirubicine/Cyclophosphamide follow Docetaxel vs. Docetaxel/Cyclophosphamide - The second primary objective study compare disease free survival randomisation patient vs. without lifestyle intervention Design : Prospectively randomize open label Phase III study 2x2 factorial design</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients may include study meet follow criterion : 1 . Primary epithelial invasive carcinoma breast pT14 , pN03 , pM0 2 . No evidence HER2/neu overexpressing ( IHC neg + ) amplifying ( FISH neg . ) tumor 3 . Histopathological proof axillary lymph node metastasis ( pN13 ) high risk node negative , define least one criterion following : 'pT ≥2 , histopathological grade 3 , age ≤35 , negative hormone receptor ' 4 . Complete resection primary tumor margin resection free invasive carcinoma 6 week ago 5 . Females ≥ 18 year age 6 . Performance status ≤ 2 ECOGScale 7 . Adequate bone marrow reserve : leucocytes ≥ 3.0 x 109/l platelet ≥ 100 x 109/l 8 . Bilirubin within reference laboratory 's normal range , ASAT ( SGOT ) , ALAT ( SGPT ) AP within 1,5 fold reference laboratory 's normal range patient 9 . Willingness participate telephonebased lifestyle intervention programme [ 10 . ] Intention regular follow visit duration study [ 11 . ] Ability understand nature study give write informed consent Patients exclude study follow reason : 1 . Inflammatory breast cancer 2 . Previous concomitant cytotoxic systemic antineoplastic treatment part study 3 . A second primary malignancy ( except situ carcinoma cervix adequately treat basal cell carcinoma skin ) 4 . Cardiomyopathy impair ventricular function ( NYHA &gt; II ) , cardiac arrhythmia influence LVEF require medication , history myocardial infarction angina pectoris within last 6 month , arterial hypertension control medication 5 . Any known hypersensitivity Docetaxel , Epirubicine , Cyclophosphamide , medication include study protocol . The contraindication , warn notice measure precaution product , notified product infroamtion , respect 6 . Use investigational agent within 3 week prior inclusion 7 . Patients pregnancy breast feeding ( premenopausal woman anticonception assure ) 8 . Insulinrequiring diabetes mellitus ( noninsulin require patient type 2 diabetes eligible study ) 9 . Serious digestive and/or absorptive problem exclude adherence study diet [ 10 . ] Selfreported inability walk least one kilometer ( pace ) [ 11 . ] Cardiovascular , respiratory musculoskeletal disease joint problem preclude moderate physical activity . Moderate arthritis preclude physical activity reason exclusion [ 12 . ] Psychiatric disorder condition would preclude participation study intervention [ 13 . ] Patients sufficiently fluent German language understand nature study interventional measure</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>